---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-24-000070"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T01:14:29.945559+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive

## Summary
- Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.
- Net loss $6.6M ($0.15/sh) vs $7.1M ($0.17/sh) in Q1 2023; adjusted net loss $2.7M ($0.06/sh).
- Adjusted EBITDA positive at $1.0M vs loss of $3.8M in prior year.
- Cash & investments $23.6M as of March 31, 2024, down from $37.0M at Dec 31, 2023.
- Reaffirmed FY2024 revenue guidance $177M-$181M; gross margin 76%-79%; expects positive net cash flow Apr-Dec 2024.

## SEC filing metadata
- accession: 0000805928-24-000070
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/axgn-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-24-000070
- JSON: https://secwatch.observer/filing/0000805928-24-000070.json
- Plain text: https://secwatch.observer/filing/0000805928-24-000070.txt

## Key facts
- Earnings Releases
  Axogen, Inc. reported full year 2024 results: revenue 177 million to 181 million. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: 177 million to 181 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: We are maintaining our annual revenue guidance in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm
- Earnings Releases
  Axogen, Inc. reported first quarter ended March 31, 2024 results: revenue 41.4 million, net income -6.6 million, EPS -0.15. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: 41.4 million
  - Net income: -6.6 million
  - EPS: -0.15
  - Guidance: reaffirmed
  - Result: reported results
  source text: First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm
- Earnings Releases
  Axogen, Inc. reported first quarter ended March 31, 2024 results: revenue 41.4 million, net income -6.6 million, EPS -0.15. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: 41.4 million
  - Net income: -6.6 million
  - EPS: -0.15
  - Guidance: reaffirmed
  - Result: reported results
  source text: nerve injuries, today reported financial results and business highlights fo r the first quarter ended March 31, 2024. First Quarter Financial Results • First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023. • In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the same quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.